USD 11.2
(3.47%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 1.02 Billion USD | 11.56% |
2022 | 917 Million USD | -32.12% |
2021 | 1.35 Billion USD | -37.45% |
2020 | 2.16 Billion USD | -32.88% |
2019 | 3.21 Billion USD | 49.47% |
2018 | 2.15 Billion USD | 19.54% |
2017 | 1.8 Billion USD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q3 | 359 Million USD | 84.1% |
2024 Q2 | 195 Million USD | -2.99% |
2024 Q1 | 201 Million USD | -63.19% |
2023 Q1 | 177 Million USD | 63.89% |
2023 Q3 | 58 Million USD | -76.03% |
2023 Q2 | 242 Million USD | 36.72% |
2023 Q4 | 546 Million USD | 841.38% |
2023 FY | 1.02 Billion USD | 11.56% |
2022 Q1 | 348 Million USD | 72.28% |
2022 FY | 917 Million USD | -32.12% |
2022 Q4 | 108 Million USD | -52.42% |
2022 Q3 | 227 Million USD | -2.99% |
2022 Q2 | 234 Million USD | -32.76% |
2021 Q2 | 427 Million USD | 7.02% |
2021 FY | 1.35 Billion USD | -37.45% |
2021 Q1 | 399 Million USD | 8.42% |
2021 Q4 | 202 Million USD | -37.46% |
2021 Q3 | 323 Million USD | -24.36% |
2020 Q4 | 368 Million USD | -32.72% |
2020 Q3 | 547 Million USD | 0.92% |
2020 Q2 | 542 Million USD | -22.9% |
2020 Q1 | 703 Million USD | 0.0% |
2020 FY | 2.16 Billion USD | -32.88% |
2019 FY | 3.21 Billion USD | 49.47% |
2018 FY | 2.15 Billion USD | 19.54% |
2017 FY | 1.8 Billion USD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
AbbVie Inc. | 4.86 Billion USD | 78.964% |
Bristol-Myers Squibb Company | 8.02 Billion USD | 87.252% |
Bristol-Myers Squibb Company Ce | 8.02 Billion USD | 87.252% |
Johnson & Johnson | 35.15 Billion USD | 97.09% |
Eli Lilly and Company | 5.24 Billion USD | 80.479% |
Merck & Co., Inc. | 365 Million USD | -180.274% |
Novartis AG | 14.85 Billion USD | 93.111% |
Pfizer Inc. | 2.11 Billion USD | 51.723% |